[go: up one dir, main page]

ES8300101A1 - Procedimiento para la obtencion de 2-oxidos de 1,2,5-oxadiazol 3,4-bis-sustituidos. - Google Patents

Procedimiento para la obtencion de 2-oxidos de 1,2,5-oxadiazol 3,4-bis-sustituidos.

Info

Publication number
ES8300101A1
ES8300101A1 ES508086A ES508086A ES8300101A1 ES 8300101 A1 ES8300101 A1 ES 8300101A1 ES 508086 A ES508086 A ES 508086A ES 508086 A ES508086 A ES 508086A ES 8300101 A1 ES8300101 A1 ES 8300101A1
Authority
ES
Spain
Prior art keywords
phosphoric acid
procedure
oxadiazole
oxides
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES508086A
Other languages
English (en)
Other versions
ES508086A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Cassella Farbwerke Mainkur AG
Original Assignee
Cassella AG
Cassella Farbwerke Mainkur AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassella AG, Cassella Farbwerke Mainkur AG filed Critical Cassella AG
Publication of ES8300101A1 publication Critical patent/ES8300101A1/es
Publication of ES508086A0 publication Critical patent/ES508086A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Materials For Photolithography (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

PROCEDIMIENTO PARA DEPOSITAR SOBRE UNA LAMINA DE SILICIO UNA PELICULA ESENCIALMENTE CONTINUA DE ACIDO FOSFORICO, LA CUAL MEDIANTE UN TRATAMIENTO ULTERIOR FORMA UNA UNION ELECTRICA P-N. COMPRENDE LAS SIGUIENTES ETAPAS: PRIMERA, SE VAPORIZA ACIDO FOSFORICO MEDIANTE LA PULVERIZACION DE ACIDO FOSFORICO EN UN TUBO CALENTADO A UNA TEMPERATURA COMPRENDIDA ENTRE 400 Y 800 GRADOS, SIENDO PORTADO DICHO ACIDO FOSFORICO POR UN GAS INERTE; SEGUNDA, SE CONDENSA EL MENCIONADO VAPOR SOBRE LA SUPERFICIE DEL SUSTRATO DE SILICIO PARA FORMAR UNA PELICULA CONTINUA; Y POR ULTIMO, SE CALIENTA LA SUPERFICIE DEL SUSTRATO DE SILICIO PARA FORMAR UNA CAPA DE OXIDO DE FOSFORO-SILICATO-CRISTAL, CON UN ESPESOR COMPRENDIDO ENTRE 90 Y 200 ~T. DE APLICACION EN LA FABRICACION DE DISPOSITIVOS MICROELECTRONICOS, TALES COMO CELULAS SOLARES.
ES508086A 1980-12-18 1981-12-17 Procedimiento para la obtencion de 2-oxidos de 1,2,5-oxadiazol 3,4-bis-sustituidos. Granted ES508086A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803047730 DE3047730A1 (de) 1980-12-18 1980-12-18 3,4-bis-substituierte 1,2,5-oxdiazol-2-oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen

Publications (2)

Publication Number Publication Date
ES8300101A1 true ES8300101A1 (es) 1982-10-01
ES508086A0 ES508086A0 (es) 1982-10-01

Family

ID=6119497

Family Applications (1)

Application Number Title Priority Date Filing Date
ES508086A Granted ES508086A0 (es) 1980-12-18 1981-12-17 Procedimiento para la obtencion de 2-oxidos de 1,2,5-oxadiazol 3,4-bis-sustituidos.

Country Status (28)

Country Link
US (1) US4356178A (es)
EP (1) EP0054872B1 (es)
JP (1) JPS57123173A (es)
KR (1) KR880000543B1 (es)
AR (1) AR227697A1 (es)
AT (1) ATE10094T1 (es)
AU (1) AU542529B2 (es)
CA (1) CA1157019A (es)
CS (1) CS219863B2 (es)
DD (1) DD201897A5 (es)
DE (2) DE3047730A1 (es)
DK (1) DK150597C (es)
ES (1) ES508086A0 (es)
FI (1) FI813666A7 (es)
GR (1) GR81375B (es)
HK (1) HK51385A (es)
HU (1) HU183751B (es)
IE (1) IE52034B1 (es)
IL (1) IL64563A (es)
NO (1) NO814045L (es)
NZ (1) NZ199272A (es)
PH (1) PH18051A (es)
PL (1) PL128564B1 (es)
PT (1) PT74129B (es)
RO (1) RO84099B (es)
SG (1) SG21285G (es)
SU (1) SU1093246A3 (es)
ZA (1) ZA818726B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507485A (en) * 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
DE4217794A1 (de) * 1992-05-29 1993-12-02 Cassella Ag Phenylfuroxane
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4218979A1 (de) * 1992-06-10 1993-12-16 Cassella Ag Pyrimidofuroxane
DE4220264A1 (de) * 1992-06-20 1993-12-23 Cassella Ag Phenyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
DE4307105A1 (de) * 1993-03-06 1994-09-08 Cassella Ag Hydroxymethylfurazancarbonsäurederivate
US5460669A (en) * 1993-06-28 1995-10-24 Thiokol Corporation 3-nitramino-4-nitrofurazan and salts thereof
DE4401150A1 (de) * 1994-01-17 1995-07-20 Cassella Ag Furazancarbonsäurederivate
EP1896017A2 (en) 2005-06-15 2008-03-12 Hydra Biosciences, Inc. Modulators of sperm hypermotility and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089867A (en) * 1976-11-11 1978-05-16 Texaco Inc. Preparation of diacylfurazan oxides

Also Published As

Publication number Publication date
FI813666L (fi) 1982-06-19
DK150597B (da) 1987-04-06
IE52034B1 (en) 1987-05-27
HK51385A (en) 1985-07-12
FI813666A7 (fi) 1982-06-19
PT74129A (de) 1982-01-01
NZ199272A (en) 1984-03-16
PL128564B1 (en) 1984-02-29
AU7855881A (en) 1982-06-24
AU542529B2 (en) 1985-02-21
DD201897A5 (de) 1983-08-17
KR880000543B1 (ko) 1988-04-13
SU1093246A3 (ru) 1984-05-15
CA1157019A (en) 1983-11-15
PT74129B (de) 1983-05-16
RO84099B (ro) 1984-06-30
ZA818726B (en) 1982-11-24
DK533881A (da) 1982-06-19
DE3047730A1 (de) 1982-07-15
PH18051A (en) 1985-03-13
US4356178A (en) 1982-10-26
PL234257A1 (es) 1982-08-02
RO84099A (ro) 1984-05-12
KR830007596A (ko) 1983-11-04
ES508086A0 (es) 1982-10-01
EP0054872B1 (de) 1984-10-31
JPS57123173A (en) 1982-07-31
DK150597C (da) 1987-10-26
AR227697A1 (es) 1982-11-30
IL64563A0 (en) 1982-03-31
EP0054872A1 (de) 1982-06-30
CS219863B2 (en) 1983-03-25
HU183751B (en) 1984-05-28
IE812976L (en) 1982-06-18
JPH0223551B2 (es) 1990-05-24
SG21285G (en) 1985-09-13
ATE10094T1 (de) 1984-11-15
DE3167001D1 (en) 1984-12-06
NO814045L (no) 1982-06-21
GR81375B (es) 1984-12-11
IL64563A (en) 1985-02-28

Similar Documents

Publication Publication Date Title
ES8300101A1 (es) Procedimiento para la obtencion de 2-oxidos de 1,2,5-oxadiazol 3,4-bis-sustituidos.
ES8303819A1 (es) Procedimiento para formar una capa de oxido de fosforo-silicato-cristail sobre la superficie de un sustrato de silicio.
ES8106817A1 (es) Un metodo para aplicar un revestimiento antirreflejante so- bre silicio
ES2088793T3 (es) Un metodo de fabricar componentes semiconductores asi como una celula solar fabricada a partir de los mismos.
KR890016629A (ko) 반도체 장치의 제조방법
JPS5621372A (en) Manufacture of semiconductor device
JPS5467778A (en) Production of semiconductor device
JPS5693375A (en) Photoelectric conversion device
US4270136A (en) MIS Device having a metal and insulating layer containing at least one cation-trapping element
CN104993009A (zh) 补偿掺杂阻挡杂质带太赫兹探测器芯片及其制备方法
CN103700731B (zh) 一种可转移碲镉汞薄膜的制备方法
CN106910682B (zh) 一种采用向改性Si薄膜引入辅助性离子提高光学性能的方法
CN106206982B (zh) 一种提高柔性基底水氧阻隔性能的结构及其制备方法
JPS5713760A (en) Semiconductor device and manufacture thereof
GB1338337A (en) Cadmium sulphide thin film sustained conductivity device and method for making same
JPS5459090A (en) Semiconductor device and its manufacture
JPS5559741A (en) Preparation of semiconductor device
JPS5646522A (en) Semiconductor device and manufacture thereof
JPS5717158A (en) Manufacture of semiconductor device
JPS54109765A (en) Manufacture of semiconductor device
JPS5214367A (en) Semiconductor device on which the phosphosilicate glass layer is formed
JPS55133556A (en) Planar semiconductor device and method of fabricating the same
JPS57201015A (en) Manufacture of semiconductor device
JPS6240453Y2 (es)
JPS54157496A (en) Manufacture of tunnel junction

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970303